 |
For Most Mild to Moderate Crohn's Patients
Send to a Colleague
If you would like to send the homepage of the ENTOCORT® EC site to a colleague, just complete the form below and click SUBMIT. Your colleague will receive an e-mail with a direct link to this information along with a notification that you requested this information be shared. We are committed to protecting your privacy. Please read our Privacy Statement.
*For Crohn’s disease involving the ileum and/or ascending colon, ENTOCORT EC is indicated for the treatment of mild to moderate active disease (up to 8 weeks with repeated 8-week courses as necessary) and the maintenance of clinical remission of mild to moderate disease for up to an additional 3 months.
Clinical remission is defined as a Crohn’s Disease Activity Index (CDAI) score of ≤150.
Important safety information
Since ENTOCORT EC® is a glucocorticosteroid (GCS), general warnings about GCSs should be followed. GCSs can reduce the response of the hypothalamus-pituitary-adrenal axis to stress. Supplementation with a systemic GCS is recommended before surgery or other stress situations. Adrenocortical function monitoring may be required in patients being transferred to ENTOCORT EC from a systemic GCS, and the dose of the systemic GCS should be reduced cautiously.
Patients on drugs that suppress the immune system are more susceptible to infections and should avoid exposure to infections such as chicken pox or measles.
Patients with moderate to severe liver disease and patients who are concomitantly taking ketoconazole or any other CYP3A4 inhibitor should be closely monitored for increased signs and/or symptoms of hypercorticism.
The adverse event profile of ENTOCORT EC in 6 mg once daily clinical trial treatment (52-week) was similar to that of 9 mg once daily clinical trial treatment (8-week). The most frequently reported adverse events in clinical trials of ENTOCORT EC were headache, respiratory infection, nausea, and symptoms of hypercorticism.
